Prime editing, known for its ability to introduce targeted insertions, deletions, or base conversions within the genome, is typically restricted to short DNA segments. Similarly, Gibson assembly is a laboratory method that allows the seamless joining of multiple DNA fragments in a controlled, single-reaction setting. By ingeniously combining these methods, prime assembly expands the horizon of genomic editing to unprecedented lengths, potentially analogous to swapping an entire paragraph or chapter in a vast genetic manuscript rather than just a single letter or word.

Erik Sontheimer, PhD, Pillar Chair in Biomedical Research and a professor specializing in RNA therapeutics, explains that existing gene editing technologies—including prime editing, base editing, and CRISPR-Cas9—are largely limited to swapping out small snippets of genetic code, comparable to editing individual characters in text. The novel prime assembly system circumvents these constraints, furnishing the capability to insert gene-length sequences efficiently and accurately, thereby addressing genetic disorders associated with large mutations or clusters of mutations dispersed across genes.

Published in the prestigious journal Nature, this research embodies a collaborative effort involving notable experts such as Wen Xue, PhD, Professor of RNA Therapeutics, Scot A. Wolfe, PhD, and several dedicated students and postdoctoral fellows from the UMass Chan community. Their collective insights and technological advancements represent a significant leap forward in precisely correcting vast genomic defects with potential clinical applications in gene therapy.

One of the primary challenges in treating genetic diseases stems from the myriad mutations present within individual genes, necessitating multiple, mutation-specific therapeutic interventions. Current technologies falter when faced with this complexity, as they excel only at small edits and require tailored approaches for each mutation, which is neither efficient nor practical. Prime assembly resolves this by enabling scientists to insert DNA insertions as long as 11,000 base pairs, encompassing entire gene sequences and thereby simplifying therapeutic design.

Technically, prime assembly employs a twin prime editing approach to generate programmable single-stranded DNA flaps at the target genomic locus. These flaps precisely anneal to complementary regions on the donor DNA, facilitating seamless integration without creating double-strand breaks (DSBs), which are prone to causing unpredictable mutations or deletions due to error-prone cellular repair mechanisms. Instead, prime assembly induces single-strand nicks, a gentler approach that minimizes deleterious consequences on genome integrity and cellular viability.

The elegance of this technology lies not only in the scale of DNA it can incorporate but also in the streamlined nature of its process compared to other large-sequence insertion methods. Traditional gene editing techniques that enable sizable insertions often involve complex viral delivery systems or induce more damaging genomic interventions. Prime assembly’s methodology bypasses these pitfalls, making it a biotechnological breakthrough with promising implications for both research and eventual clinical translation.

Another remarkable advantage of prime assembly is its effectiveness in nondividing cells, such as neurons. Many current gene editing modalities are optimized for dividing cells, limiting their utility in treating neurological disorders or other conditions involving quiescent cells. By operating efficiently within cells that do not frequently divide, prime assembly opens avenues for addressing a broader array of diseases previously deemed inaccessible to gene replacement therapies.

Moreover, prime assembly’s intrinsic capacity to join multiple DNA fragments mirrors the functionality of Gibson assembly in vitro but accomplishes it within the genomic context. This ability to stitch together several DNA strands endogenously broadens possibilities for creating more complex genetic modifications, including the insertion of synthetic genes, regulatory sequences, or entire genomic loci, which could revolutionize synthetic biology and therapeutic gene design.

Looking ahead, the research team aims to unravel the precise endogenous cellular mechanisms that prime assembly engages to mediate DNA joining within the genome. A deeper understanding of these native processes may illuminate how to further enhance the efficiency and safety of prime assembly, while also guiding its adaptation to diverse cell types and organisms. Parallelly, preclinical studies in animal models are poised to evaluate the therapeutic potentials and biosafety of this technology, fostering progress toward clinical applications.

The development of prime assembly represents a critical advance toward the overarching goal of gene therapy: to create versatile, efficient, and broadly applicable tools capable of repairing the vast spectrum of genetic mutations that underlie human disease. By enabling the insertion of large DNA sequences with precision and minimal genomic disruption, prime assembly stands to transform the landscape of genetic medicine, offering hope for patients with complex genetic disorders.

UMass Chan Medical School, home to this breakthrough research, is a hub of innovation, integrating cutting-edge biomedical science with translational initiatives aimed at addressing global health challenges. Their interdisciplinary approach combines expertise in RNA therapeutics, molecular biology, and genetic engineering, nurturing an environment where transformative technologies like prime assembly can emerge and thrive.

As the field of genome engineering continues to expand rapidly, prime assembly sets a new benchmark for what is achievable in editing the human genome. Its convergence of prime editing’s precision and Gibson assembly’s assembly prowess encapsulates the future of gene therapy: precise, scalable, and capable of tackling genetic diseases at an unprecedented scale and complexity.

The implications of this technology extend beyond gene therapy alone, impacting research areas such as functional genomics, synthetic biology, and regenerative medicine. With its ability to rewrite extensive sections of the genome, prime assembly empowers researchers to probe genetic functions in greater detail and devise innovative strategies to counteract disease.

In conclusion, the advent of prime assembly redefines the frontier of genomic editing, heralding a new era where entire genes, not just snippets, can be seamlessly edited, inserted, and replaced. This landmark innovation aligns with the vision of personalized medicine, promising tailored, effective treatments for patients burdened by the complexity of genetic disease.

Subject of Research: Cells

Article Title: Prime assembly with linear DNA donors enables large genomic insertions

News Publication Date: April 29, 2026

Web References:
https://www.nature.com/articles/s41586-026-10460-4

References:
Sontheimer, E., Xue, W., et al. (2026). Prime assembly with linear DNA donors enables large genomic insertions. Nature. DOI: 10.1038/s41586-026-10460-4.

Image Credits: Bryan Goodchild, UMass Chan Medical School

Keywords: Gene editing, Gene therapy, Genetics, Genetic engineering, Gene delivery, Genomics, Human genetics, Molecular genetics, Molecular biology, Nucleic acids

This innovative technology, detailed in a study published on April 29, 2026, in the journal Nature, builds upon the foundation of prime editing—a precise gene-editing technique combining CRISPR-Cas9 and reverse transcriptase capabilities. The team of researchers, led collaboratively by Bin Liu of The Ohio State University College of Medicine and colleagues from the University of Massachusetts Chan Medical School, devised a method incorporating overlapping DNA flaps that seamlessly integrate donor DNA into the genome without causing the harmful double-strand breaks traditionally associated with large DNA insertions.

Prime assembly deftly circumvents the cytotoxic pitfalls commonly attributed to double-strand breaks in DNA, which can lead to cell death and hinder therapeutic efficacy. By leveraging programmable single-stranded DNA “flaps” generated via twin prime editing strategies, the system fosters a scenario where donor DNA with up to an astonishing 11,000 base pairs can be accurately inserted, representing a quantum leap over the previous limit of approximately 800 base pairs in gene editing. This capacity to transplant vast genetic sequences enables the correction of multiple heterogeneous mutations within a single therapeutic intervention, a feat previously considered unattainable due to regulatory and technical constraints.

The significance of this capability cannot be overstated. Many debilitating genetic diseases are caused by a constellation of mutations scattered throughout a gene or its regulatory regions. Traditional gene therapy approaches would require addressing these mutations individually, complicating development pipelines and requiring multiple approvals. Prime assembly simplifies this by replacing substantial genetic regions wholesale, akin to excising entire paragraphs or chapters from a genome “book” and replacing them with fresh, precise sequences that restore functionality.

Mechanistically, the process involves preparing the donor DNA in the laboratory, which serves as the “healthy” genetic template for insertion. The twin prime editing system creates complementary overlapping flaps on the target DNA locus. These flaps hybridize with ends of the donor DNA, enabling its integration into the genome without the need for error-prone DNA repair pathways like homology-directed repair, which is only efficient in dividing cells. This innovation notably broadens therapeutic applicability to non-dividing cells such as neurons and cardiomyocytes, cell types previously elusive targets for gene therapy.

The team’s in vitro assays in mammalian cells demonstrated not only the impressive efficiency of prime assembly but also its potential safety advantages, as the technique induces only a single-strand DNA break. Such breaks are less detrimental and less likely to trigger apoptosis or other adverse cellular responses compared to double-strand breaks. This attribute positions prime assembly as a powerful candidate for in vivo therapeutic applications where maintaining cellular integrity is paramount.

Further advancing translational potential, the researchers emphasized ongoing work to optimize delivery systems for both the donor DNA and gene editor components. Based on current gene therapy modalities, lipid nanoparticles or adeno-associated viruses (AAVs) are considered the leading vectors to transport these genetic payloads into patients’ cells effectively and safely. The versatility of prime assembly’s design promises compatibility with these delivery vehicles, setting the stage for imminent preclinical and clinical explorations.

Prime assembly inherits its name in homage to Gibson assembly cloning, a widely used molecular biology technique that joins multiple DNA fragments in vitro. Whereas Gibson assembly has revolutionized DNA construction in test tubes, prime assembly translates a similar conceptual framework into a cellular context, effecting large and precise genomic insertions directly inside living cells.

Looking ahead, the research team, including collaborators from Ohio State’s Gene Therapy Institute and experts like ophthalmologist Tom Mendel, plans to rigorously evaluate the efficacy, specificity, and safety of prime assembly in animal models. Such studies will critically inform its readiness for clinical application, potentially transforming treatment paradigms for a host of genetic disorders that have long eluded cure due to their complexity.

Underpinning this scientific leap are extensive collaborative efforts supported by prominent institutions such as the National Institutes of Health, the Leducq Foundation Transatlantic Network of Excellence Program, and the Cystic Fibrosis Foundation. These partnerships reflect the interdisciplinary and high-stakes nature of gene therapy research that melds cutting-edge molecular biology with patient-centered translational goals.

In sum, prime assembly emerges as a beacon of hope in the gene therapy field, promising to unlock large-scale genomic insertions hitherto thought impossible without compromising cell viability. The capacity to insert entire healthy genes tailored to a patient’s unique mutation spectrum could revolutionize treatment options, driving precision medicine deeper into the realm of curative care for heretofore intractable genetic diseases.

The long-term impact of prime assembly technology extends beyond therapeutic applications. It also offers a versatile platform for fundamental research, allowing scientists to study gene function and genomic architecture with unparalleled precision by introducing large, customizable DNA sequences into the genome. This may accelerate discovery across genetics, developmental biology, and regenerative medicine.

As prime assembly continues to mature through successive iterations of experimental validation, its transformative potential will likely catalyze new biotech innovations, spawning a generation of gene therapies that transcend the limitations of existing editing approaches. The future where complex genetic diseases can be robustly treated or cured through large-scale genomic replacement now feels within reach, marking a watershed moment in the annals of biomedical science.

— Written by Emily Caldwell, Emily.Caldwell@osu.edu

Subject of Research: Gene editing technology enabling large genomic insertions via prime assembly

Article Title: Prime assembly with linear DNA donors enables large genomic insertions

News Publication Date: 29-Apr-2026

Web References: https://www.nature.com/articles/s41586-026-10460-4

References: Liu B. et al., “Prime assembly with linear DNA donors enables large genomic insertions,” Nature, April 29, 2026.

Image Credits: Not provided

Keywords

Gene therapy, Prime editing, Large DNA insertion, Genome editing, Twin prime editing, Non-dividing cells, Single-strand break, Homology-directed repair, Lipid nanoparticle delivery, Adeno-associated virus, Genetic disease, Precision medicine